Large CRE Deals Come Roaring Back: What Q3 2025 Means for Today’s Professionals

City skyline sunrise

After several quarters of hesitation, the U.S. commercial real estate market saw a major pulse of confidence in Q3 2025. According to fresh data from Altus Group, large single‑asset deals valued at $10 million or more surged back into the spotlight, hitting $76 billion for the quarter — the strongest performance since 2022.

For professionals across real estate, finance, and investment sectors, this shift isn’t just a statistic. It’s a directional signal: liquidity is returning, high‑value buyers are stepping back in, and the upper tier of the market is showing long‑awaited signs of normalization.

The Return of the Big Deal

Altus Group’s Q3 2025 Investment & Transactions Report reveals a notable trend reversal. For the first time in several quarters, both quarterly and annual deal counts increased. But what truly stands out is the composition — large, single‑asset transactions made a powerful comeback.

Q3 2025 recorded 1,826 single‑asset deals above $10M — the highest since Q3 2022.

This accounted for nearly 68% of all single‑asset dollars traded, a level not seen since mid‑2022. Even outside the record‑breaking volatility of the post‑pandemic period, this quarter delivered the strongest growth rate for major deals in more than a decade.

A Market Rebound — But Not a Full Return to Peak Conditions

Despite the strong resurgence in activity, overall transaction volume still trails the highs of 2021 and 2022. The main cause? Deal size. The median large‑deal value landed at $19.6 million, roughly 9% below the late 2021 peak of $21.4 million.

Every major sector remains below its historic high:

Industrial: 1.7% below peak
Multifamily: 8.2% below peak
Office: 23.8% below peak
Retail: 6.1% below peak

Office continues to be the long‑term laggard, while industrial remains closest to full recovery. Multifamily, meanwhile, is showing renewed momentum with a 14.2% rise from post‑pandemic lows.

Pricing Trends Hint at Stabilization

The median price per square foot across property types rose 0.6% both quarterly and annually — a subtle but encouraging sign of stabilization. Office properties, however, continue their downward drift, losing 3% QoQ and 4.4% YoY.

Investors appear increasingly comfortable re‑entering the market, even if valuations remain below peak highs — suggesting improved price discovery and growing confidence in long‑term underwriting.

Why This Matters for Today’s Professionals

Commercial real estate often acts as a barometer for broader economic risk appetite. The return of large‑scale deals signals that institutional players believe conditions are returning to equilibrium. For real estate agents, mortgage professionals, and investors, this means new opportunities are emerging.

For those looking to upskill or transition into CRE roles, now is the time to enhance your professional profile. Schools like Cameron Academy provide flexible, career‑focused licensing and continuing education designed to keep professionals competitive during shifting market cycles.

A Step Toward Market Normalization

The key question now: will this momentum continue? As borrowing costs settle and underwriting clarity improves, Q4 and early 2026 could bring even greater liquidity — or a cautious pause.

For now, Q3 stands as the clearest sign in years that capital is flowing back into the big‑deal segment — and that investors are once again ready to make meaningful, future‑focused moves.

Read the full Altus Group analysis

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

The AI Boom in Cancer: Game-Changer or Just Hype?

The promise of artificial intelligence (AI) in the field of oncology is nothing short of revolutionary. As the world grapples with the complexities of cancer, AI is emerging as a potential game-changer in diagnostics, treatment personalization, and drug discovery.

By |January 15, 2025|Categories: Article, Healthcare, Technology|Tags: |0 Comments

HHS Unveils AI Strategic Plan to Revolutionize Healthcare

The U.S. Department of Health and Human Services (HHS) has unveiled its ambitious AI Strategic Plan, a comprehensive blueprint aimed at revolutionizing healthcare, human services, and public health through the transformative power of artificial intelligence.

By |January 15, 2025|Categories: Article, Artificial Intelligence, Healthcare|Tags: , |0 Comments

United States Naval Academy Class of 2024 Graduation

The ceremony was graced by the presence of three distinguished speakers, whose words of wisdom and encouragement left a lasting impression on the attendees.

By |January 14, 2025|Categories: Article, Education, Military|Tags: , |0 Comments

AI Certifications: The Key to Future-Proofing Your Career

In the fast-paced world of artificial intelligence (AI), staying current with the latest technological advancements is crucial for professionals aiming to excel in their careers. As businesses increasingly integrate AI into their operations, the demand for skilled AI experts is surging.

By |January 14, 2025|Categories: Article, Education, Technology|Tags: , |0 Comments

Telemedicine: A Digital Revolution in Healthcare Amid COVID-19

The year 2020 marked a significant turning point in the global healthcare landscape, as the COVID-19 pandemic accelerated the adoption of digital technologies such as telemedicine.

By |January 14, 2025|Categories: Article, Healthcare, Technology|Tags: , |0 Comments

Genomic Biomarkers Market Thrives with Personalized Medicine Boom

The genomic biomarkers market is witnessing a significant surge, driven by the burgeoning demand for personalized medicine. According to the latest report, the market is projected to grow to $14.09 billion by 2028, marking a compound annual growth rate (CAGR) of 17.4%. This approach not only optimizes treatment effectiveness but also minimizes side effects, making it a cornerstone of modern healthcare.